What are the opening hours?

Monday 09:00 - 17:45 Tuesday 10:00 - 20:00 Wednesday 10:00 - 20:00 Thursday 10:00 - 20:00 Friday 10:00 - 20:00

Onco. Treatments Pvt Ltd, 2nd Floor, Zul Jalal Centre, Main Tariq Road, PECHS, Karachi (2026)

11/11/2025

Improve Soft Tissue Sarcoma Treatment PDQ with Hyperthermia.

Clinical results like the one below reveal that Chemotherapy treatment is more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Clinical Evidence
Tumor Entity:
Soft tissue sarcoma primary or locally recurrent both of the trunk and the extremities.

Treatment Modality:
Primary or locally recurrent soft tissue sarcoma, both of the trunk and the extremities, were treated with 4 cycles of chemotherapy, Etoposide, Iphosphamide and Adriamycin, both pre and post local treatment. Patients were randomized to additional hyperthermia or not. All contributing centers have been using the BSD-2000 and BSD-2000-3D devices.

Disease Free Survival after 7 years (Issels 2010)
Chemotherapy EIA alone: 21%
Chemotherapy EIA plus Hyperthermia: 42%
sarcoma graph

Endorsements:
ESMO European Society of Medical Oncology – level I, Europe
NCCN National Cancer Center Network Treatment Guidelines – level 1B, USA
Chemotherapy and Hyperthermia:
When hyperthermia is combined with chemotherapy, general treatment guidelines of the ESHO European Society of Hyperthermic Oncology recommend:

Target volume for hyperthermia: The target volume for hyperthermia is the gross tumor volume.
Sequence of treatment modalities: Hyperthermia is given simultaneously with chemotherapy during cytostasis.
Duration of hyperthermia treatment: Superficial hyperthermia total 60 minutes, deep hyperthermia total 90 minutes (including 30 minutes heating-up time)

References:
R.D.Issels et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010 Jun;11(6):561-70.

Issels RD. Regional hyperthermia in high-risk soft tissue sarcomas. Curr Opin Oncol. 2008 Jul;20(4):438-43.

Issels et al. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised prospective trial (EORTC/ESHO intergroup trial). J Clin Oncol.. 2007; Volume 25, Issue 18S-June 20.

Wendtner et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts longterm survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. 2002 Jul 15;20(14):3156-64.
ESMO / European Sarcoma Network Working Group: Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9.
NCCN Clinical Practice Guidelines in Oncology™ Soft Tissue Sarcoma, Version 2.2011

11/11/2025

Improve Esophageal Cancer Treatment Results with Hyperthermia.

Esophageal (Oesophageal) cancer is the eighth most common cancer worldwide according to the World Cancer Research Fund International. With nearly 456,000 new cases diagnosed in 2012. About 75% of those cases are diagnosed in Asia.

Level 1 Clinical results like the one below reveal that both Chemotherapy and Radiation treatment are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Clinical Evidence
Tumor Entity:
Primary thoracic esophageal cancer stage III and IV

Treatment Modality:
Three randomized studies were performed in esophageal cancer, comparing radio and/or chemotherapy with or without intraluminal hyperthermia. Kitamura et al. compared preoperative radiochemotherapy with or without hyperthermia. Wang et al. compared 60 Gy alone to 40 Gy plus hyperthermia. Sugimachi et al. compared preoperative chemotherapy with or without hyperthermia. Third party hyperthermia devices used.

esophagus ht table

Clinical Results:
Kitamura et al. found a significantly higher pCR in the plus hyperthermia treatment arm: 25% vs 6%.

Wang et al. found a significantly better 3-y overall survival with hyperthermia: 42 vs 24%.

Sugimachi et al. found that the local effects tended to be better in the plus hyperthermia group: improvement of dysphagia 70% vs 40%; radiographic improvement 50% vs 25%, and histopathological evidence of treatment effect 41% vs 19%.

Duration of hyperthermia treatment
Intraluminal hyperthermia total 30 minutes

References:
Kitamura et al. Prospective Randomised Study of Hyperthermia Combined with Chemoradiotherapy for Esophageal Carcinoma. J Surgical Oncology. 1995; 60:55-58.

Wang et al. Intracavitary microwave hyperthermia combined with external irradiation in the treatment of esophageal cancer. Chung Hua Chung Liu Tsa Chih 1996;18:51-54.

Sugimachi et al. Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma: a prospective trial. Int J Hyperthermia 1994;10:485-4

11/11/2025

Improve Pediatric Tumor Treatment with Hyperthermia.

Pediatric soft tissue sarcomas (STS) is a heterogeneous group of malignant tumors that account for 7% of all childhood tumors. Fortunately, cancer in children and adolescents is rare, although incidents have been increasing since 1975.

Clinical results like the ones below reveal that Chemotherapy treatments are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Treatment Modality:
Hyperthermia in addition to chemotherapy was investigated as second line treatment in children with soft tissue sarcomas, and in children with refractory or recurrent germ cell tumors. Chemotherapy consisted of VP16 100 mg/m2, ifosfamide 2000 mg/m2, and CDDP 40 mg/m2, delivered over 4 days. Hyperthermia was applied on the 1st and 4th day.

Clinical Results
In soft tissue sarcoma the combined treatment resulted in 40% 3-7 years overall survival

hyper pei graph

In germ cell tumors the combined treatment resulted in a high overall survival, especially in children who were treated for a refractory tumor or a first relapse

germ cell graph

Treatment Modality:
In patients with a first relapse, the results of children treated with the combination were compared to those in matched controls treated with chemotherapy alone, which data were available from the Registry of the German Society for Pediatric Oncology & Hematology. Five-year overall survival was 38% for children treated with chemotherapy alone, while it was 93% for children treated with chemotherapy and hyperthermia. BSD-2000 and BSD-2000/3D/MR used in Düsseldorf UMC site.

Endorsement:
Additional hyperthermia is considered standard of care for children with a recurrent sarcoma or germ cell tumor by the German Society for Pediatric Oncology & Hematology.

References:
Wessalowski et al. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single institution, phase 2 study. Lancet Oncology 2013 July 1 (online).
Wessalowski et al. An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr. 2003 Nov-Dec;215(6):303-9.
Schneider et al. Treatment of recurrent malignant sacrococcygeal germ cell tumors: analysis of 22 patients registered in the German protocols MAKEI 83/86, 89, and 96. J Clin Oncol. 2001 Apr 1;19(7):1951-60.

11/11/2025

Interested in starting a hyperthermia oncology service at your cancer center?

Do you currently offer hyperthermia but would like more training?
Are you interested in increasing your center's revenue stream?
These questions will be answered, plus hands-on training in superficial, interstitial (BSD-500), deep regional hyperthermia (BSD-2000), alongside the thermal medicine community's most experienced hyperthermia experts. Whether you are a physician, physicist, RT, nurse, or practice manager, you will benefit from the experience of this two-day intensive course.

Developed by the world-renowned University of Maryland, attending this CME-credited program will ultimately benefit your patients.

29/10/2025

International Journal of Hyperthermia.

The official journal of the Society for Thermal Medicine, the European Society for Hyperthermic Oncology, and the Japanese Society of Hyperthermic Oncology, the International Journal of Hyperthermia provides a forum for the publication of research and clinical studies and trials on hyperthermia which fall largely into the three main categories of clinical studies, biological studies and techniques of heat delivery and temperature measurement.

Published by Taylor & Francis Group.

New to read at the International Journal of Hyperthermia

International Journal of Hyperthermia.

The official journal of the Society for Thermal Medicine, the European Society for Hyperthermic Oncology, and the Japanese Society of Hyperthermic Oncology, the International Journal of Hyperthermia provides a forum for the publication of research and clinical studies and trials on hyperthermia which fall largely into the three main categories of clinical studies, biological studies and techniques of heat delivery and temperature measurement.

Published by Taylor & Francis Group.

29/10/2025

Improve Pediatric Tumor Treatment with Hyperthermia

Pediatric soft tissue sarcomas (STS) is a heterogeneous group of malignant tumors that account for 7% of all childhood tumors. Fortunately, cancer in children and adolescents is rare, although incidents have been increasing since 1975.

Clinical results like the ones below reveal that Chemotherapy treatments are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Treatment Modality:
Hyperthermia in addition to chemotherapy was investigated as second line treatment in children with soft tissue sarcomas, and in children with refractory or recurrent germ cell tumors. Chemotherapy consisted of VP16 100 mg/m2, ifosfamide 2000 mg/m2, and CDDP 40 mg/m2, delivered over 4 days. Hyperthermia was applied on the 1st and 4th day.

Clinical Results
In soft tissue sarcoma the combined treatment resulted in 40% 3-7 years overall survival

In germ cell tumors the combined treatment resulted in a high overall survival, especially in children who were treated for a refractory tumor or a first relapse

reatment Modality:
In patients with a first relapse, the results of children treated with the combination were compared to those in matched controls treated with chemotherapy alone, which data were available from the Registry of the German Society for Pediatric Oncology & Hematology. Five-year overall survival was 38% for children treated with chemotherapy alone, while it was 93% for children treated with chemotherapy and hyperthermia. BSD-2000 and BSD-2000/3D/MR used in Düsseldorf UMC site.

Endorsement:
Additional hyperthermia is considered standard of care for children with a recurrent sarcoma or germ cell tumor by the German Society for Pediatric Oncology & Hematology.

References:
Wessalowski et al. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single institution, phase 2 study. Lancet Oncology 2013 July 1 (online).

Wessalowski et al. An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr. 2003 Nov-Dec;215(6):303-9.

Schneider et al. Treatment of recurrent malignant sacrococcygeal germ cell tumors: analysis of 22 patients registered in the German protocols MAKEI 83/86, 89, and 96. J Clin Oncol. 2001 Apr 1;19(7):1951-60.

29/10/2025

Improve Esophageal Cancer Treatment Results with Hyperthermia.

Esophageal (Oesophageal) cancer is the eighth most common cancer worldwide according to the World Cancer Research Fund International. With nearly 456,000 new cases diagnosed in 2012. About 75% of those cases are diagnosed in Asia.

Level 1 Clinical results like the one below reveal that both Chemotherapy and Radiation treatment are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Clinical Evidence
Tumor Entity:
Primary thoracic esophageal cancer stage III and IV

Treatment Modality:
Three randomized studies were performed in esophageal cancer, comparing radio and/or chemotherapy with or without intraluminal hyperthermia. Kitamura et al. compared preoperative radiochemotherapy with or without hyperthermia. Wang et al. compared 60 Gy alone to 40 Gy plus hyperthermia. Sugimachi et al. compared preoperative chemotherapy with or without hyperthermia. Third party hyperthermia devices used.

29/10/2025

Improve Breast Cancer Treatment Results with Hyperthermia

Breast cancer is the most common cancer in women worldwide according to the World Cancer Research Fund International. With nearly 2 million new cases diagnosed in 2018 (second most common cancer overall). This represents about 12% of all new cancer cases and 25% of all cancers in women.

Clinical results like the one below reveal that both Chemotherapy and Radiation treatment are more effective when combined with Hyperthermia. Hyperthermia warms the tumor to temperatures in the "fever range" which makes the cancer cells more sensitive to treatment. Normal healthy cells recover while cancer cells die.

Randomized trial of hyperthermia and radiation for superficial tumors, Jones et al.

Recurrent chest wall tumor with hyperthermia Jones Study
By adding twice-weekly hyperthermia treatments to the daily radiation therapy treatments, the success rate for complete response (no cancer) was tripled. Hyperthermia is known to increase blood flow and perfusion, prevent damaged cancer cells from repairing during treatment, and helping the body's immune system identify and destroy cancer cells.

Clinical Results:
One hundred twenty-two patients were enrolled; 109 (89%) were deemed heatable and were randomly assigned. The complete response rate was 66.1% in the HT arm and 42.3% in the no-HT arm. The odds ratio for complete response was 2.7 (95% CI, 1.2 to 5.8; P = .02). Previously irradiated patients had the greatest incremental gain in complete response: 23.5% in the no-HT arm versus 68.2% in the HT arm. No overall survival benefit was seen.

Randomized trial of hyperthermia and radiation for superficial tumors, Jones et al.

29/10/2025

How the Pyrexar BSD-500 Treat Breast Cancer.

MA 120 The MA-120 applicator with a water bolus is placed in skin contact over the tumor area. Deionized water is circulated into the bolus during treatment. The circulating water has three purposes; 1) complete surface contact to assist in directing RF energy toward the tumor; 2) manage patient comfort by cooling skin surface; 3)by adjusting bolus temperature, RF energy depth can be controlled. 1 to 2 treatments per week are generally prescribed along with radiotherapy and chemotherapy treatments.

18/09/2025

Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation

Brief Summary
This phase I trial studies the side effects and best way to give hyperthermia and high dose rate radiation therapy in treating patients with prostate cancer that has come back after prior radiation treatment. Radiation therapy, such as high dose rate brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Hyperthermia therapy may make tumor cells more sensitive to the effects of radiation therapy by heating them to several degrees above normal body temperature. Giving hyperthermia and high dose rate radiation therapy may work better in treating patients with recurrent prostate cancer after radiation.
Detailed Description

PRIMARY OBJECTIVES:

I. To assess the safety and feasibility of combined single fraction high dose rate (HDR) brachytherapy followed immediately by interstitial hyperthermia treatment of radio-recurrent prostate cancer.

SECONDARY OBJECTIVES:

I. To assess long-term toxicity. II. To provide a preliminary assessment of efficacy. III. To obtain blood for future analysis of immune response to combined radiation therapy and hyperthermia.

OUTLINE:

Patients undergo high dose rate brachytherapy for 15-30 minutes. Immediately after radiation therapy (no longer than 90 minutes), patients undergo interstitial hyperthermia treatment for up to 60 minutes.

After completion of study treatment, patients are followed up at 1 week, 1 month, and every 3 months for 2 years, every 6 months for 3 years and annually thereafter.

Official Title
Phase I Study of Hyperthermia Combined With High Dose Rate Salvage Radiotherapy for the Treatment of Radiation Recurrent Prostate Cancer

Conditions
Recurrent Prostate Carcinoma
Intervention / Treatment
Radiation: High-Dose Rate Brachytherapy
Procedure: Hyperthermia Treatment
Other: Laboratory Biomarker Analysis

17/09/2025

IGHT treating patients in Tübingen

On June 17, Tübingen University Hospital officially inaugurated its new BSD-2000 3D/MR Image-Guided Hyperthermia System (IGHT), supplied by Pyrexar Medical/Dr. Sennewald Medizintechnik GmbH/ and Philips Healthcare.

Image-Guided Hyperthermia uses live MRI images to verify optimal tumor temperature to ensure optimal radiosensitizing benefits of the therapy. This non-invasive approach allows the operator to move the thermal zone or adjust power output with a touchscreen interface. The steering process avoids patient applicator repositioning or the interruption of treatment, improving workflow and thermal dose.

This state-of-the-art system will be shared by the Clinic for Radiation Oncology and the Department of Diagnostic and Interventional Radiology. In this way, it not only serves cancer treatment but will also be used for diagnostic imaging, primarily for pediatric radiology.

The photo above shows those taking part in the celebrations: (left to right, Copyright Universitätsklinikum Tübingen/Janina Fischer) Prof. Dr. Daniel Zips (Director of the University Department of Radiation Oncology), Susanne Schäfer (MTA in radiology), Prof. Dr. Michael Bamberg (Chief Medical Director and Chairman of the Executive Board), Dr. Gerhard Sennewald (CEO), Prof. Dr. Konstantin Nikolaou (Director of the University Department of Radiology and of Diagnostic and Interventional Radiology), Prof. Dr. Jürgen Schäfer (Head of Pediatric Radiology), and Thomas Richter of Philips GmbH.

17/09/2025

IGHT treating patients in Tübingen

Tübingen University Hospital officially inaugurated its new BSD-2000 3D/MR Image-Guided Hyperthermia System (IGHT), supplied by Pyrexar Medical/Dr. Sennewald Medizintechnik GmbH/ and Philips Healthcare.

Image-Guided Hyperthermia uses live MRI images to verify optimal tumor temperature to ensure optimal radiosensitizing benefits of the therapy. This non-invasive approach allows the operator to move the thermal zone or adjust power output with a touchscreen interface. The steering process avoids patient applicator repositioning or the interruption of treatment, improving workflow and thermal dose.

This state-of-the-art system will be shared by the Clinic for Radiation Oncology and the Department of Diagnostic and Interventional Radiology. In this way, it not only serves cancer treatment but will also be used for diagnostic imaging, primarily for pediatric radiology.

The photo above shows those taking part in the celebrations: (left to right, Copyright Universitätsklinikum Tübingen/Janina Fischer) Prof. Dr. Daniel Zips (Director of the University Department of Radiation Oncology), Susanne Schäfer (MTA in radiology), Prof. Dr. Michael Bamberg (Chief Medical Director and Chairman of the Executive Board), Dr. Gerhard Sennewald (CEO), Prof. Dr. Konstantin Nikolaou (Director of the University Department of Radiology and of Diagnostic and Interventional Radiology), Prof. Dr. Jürgen Schäfer (Head of Pediatric Radiology), and Thomas Richter of Philips GmbH.

Onco. Treatments Pvt Ltd

11/11/2025

11/11/2025

11/11/2025

11/11/2025

29/10/2025

29/10/2025

29/10/2025

29/10/2025

29/10/2025

18/09/2025

17/09/2025

17/09/2025

Address

Opening Hours

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Monday	09:00 - 17:45
Tuesday	10:00 - 20:00
Wednesday	10:00 - 20:00
Thursday	10:00 - 20:00
Friday	10:00 - 20:00